ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
128.211,62
-0,24%
S&P 500
5.308,15
1,17%
US Dollar vs BRL
5,135
0,11%
Bitcoin
65.857,78
7,00%
Brent Oil
82,73
0,22%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Adagene Inc (ADAG)

  7. Adagene Inc (ADAG) Notícias

ADAG

Adagene (ADAG)

Adagene Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:ADAG
DataHoraFonteTítuloCódigoCompanhia
29/03/202410:00GlobeNewswire Inc.Adagene Reports Full Year 2023 Financial Results and Provides Corporate UpdateNASDAQ:ADAGAdagene Inc
07/03/202418:01GlobeNewswire Inc.Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory BoardNASDAQ:ADAGAdagene Inc
01/03/202418:30Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:ADAGAdagene Inc
27/02/202410:00GlobeNewswire Inc.Adagene to Present at the Leerink Partners Global Biopharma Conference 2024NASDAQ:ADAGAdagene Inc
09/02/202408:08Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ADAGAdagene Inc
09/02/202408:00GlobeNewswire Inc.Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsatellite-stabNASDAQ:ADAGAdagene Inc
16/01/202419:01GlobeNewswire Inc.Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)NASDAQ:ADAGAdagene Inc
04/01/202407:00GlobeNewswire Inc.Adagene To Present Interim Results of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at ASCO-GI SymposiumNASDAQ:ADAGAdagene Inc
03/11/202313:00GlobeNewswire Inc.Adagene Presents Data Demonstrating the Best-in-Class Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 at SITC 2023NASDAQ:ADAGAdagene Inc
12/10/202309:00GlobeNewswire Inc.Adagene Announces Poster Presentation on Optimal Dose Selection for Masked Anti-CTLA-4 SAFEbody® ADG126 at Upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual MeetingNASDAQ:ADAGAdagene Inc
07/09/202307:00GlobeNewswire Inc.Adagene to Present at Investor and Scientific Conferences in SeptemberNASDAQ:ADAGAdagene Inc
31/08/202308:32GlobeNewswire Inc.Adagene Reports Six Month Financial Results for 2023 and Provides Corporate UpdateNASDAQ:ADAGAdagene Inc
04/05/202310:01Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:ADAGAdagene Inc
04/05/202310:00GlobeNewswire Inc.Adagene Achieves $3 Million Milestone in Collaboration with Exelixis for Successful Nomination of Second SAFEbody® Novel Masked Antibody-Drug ConjugateNASDAQ:ADAGAdagene Inc
28/04/202308:03Edgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)NASDAQ:ADAGAdagene Inc
28/04/202308:00GlobeNewswire Inc.Adagene Announces Updates to its Board of DirectorsNASDAQ:ADAGAdagene Inc
18/04/202310:17GlobeNewswire Inc.Adagene Presents Clinical Data for Anti-CTLA-4 SAFEbody® ADG126 Reinforcing Best-in-Class Safety Profile at Repeat Doses and Showing Early Efficacy Profile in Advanced/Metastatic Solid TumorsNASDAQ:ADAGAdagene Inc
28/03/202317:30GlobeNewswire Inc.Adagene Reports Full Year 2022 Financial Results and Provides Corporate UpdateNASDAQ:ADAGAdagene Inc
14/03/202319:00GlobeNewswire Inc.Adagene Announces Poster Presentations on Anti-CTLA-4 SAFEbody®, ADG126, at Upcoming American Association for Cancer Research (AACR) Annual Meeting in AprilNASDAQ:ADAGAdagene Inc
05/03/202321:39GlobeNewswire Inc.Adagene Appoints Professor Aurélien Marabelle to Scientific and Strategic Advisory BoardNASDAQ:ADAGAdagene Inc
09/02/202310:16Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:ADAGAdagene Inc
09/01/202309:00GlobeNewswire Inc.Adagene Announces Interim Data Demonstrating Safety and Confirmed Clinical Responses of Anti-CTLA-4 SAFEbody® ADG126 up to 10 mg/kg with Repeat Cycles in Combination with Anti-PD-1 Therapy from Dose Escalation Portion of Phase 1b/2 TrialNASDAQ:ADAGAdagene Inc
05/01/202318:01GlobeNewswire Inc.Adagene to Present at the Biotech Showcase™ 2023 in San Francisco on January 9NASDAQ:ADAGAdagene Inc
16/12/202208:30GlobeNewswire Inc.Adagene Announces Clinical Trial Collaboration to Evaluate Anti-CTLA-4 SAFEbody® ADG126 in Combination with Roche’s Standard-of-Care for First-Line Advanced Liver CancerNASDAQ:ADAGAdagene Inc
21/11/202218:05GlobeNewswire Inc.Adagene Appoints Cuong Do to Board of Directors and Audit CommitteeNASDAQ:ADAGAdagene Inc
10/11/202211:04GlobeNewswire Inc.Adagene Announces Clinical Data at SITC 2022 on Anti-CTLA-4 NEObody™, ADG116, Showing Differentiated Safety and Anti-tumor Activity in Heavily Pre-treated Patients with Difficult-to-Treat TumorsNASDAQ:ADAGAdagene Inc
11/10/202217:03GlobeNewswire Inc.Adagene Announces Poster Presentations on Anti-CTLA-4 NEObody™, ADG116, at Upcoming Society for Immunotherapy of Cancer’s (SITC) Annual Meeting in NovemberNASDAQ:ADAGAdagene Inc
10/09/202205:13GlobeNewswire Inc.Adagene Presents Interim Monotherapy Data at ESMO 2022 Showing Compelling Safety, Anti-Tumor Activity and Pharmacokinetics of Masked, Anti-CTLA-4 SAFEbody® ADG126 in Patients with Advanced TumorsNASDAQ:ADAGAdagene Inc
30/08/202218:25GlobeNewswire Inc.Adagene Reports Financial Results for the Six Months Ended June 30, 2022 and Provides Corporate UpdatesNASDAQ:ADAGAdagene Inc
29/06/202217:05GlobeNewswire Inc.Adagene Announces Authorization of Share Repurchase Program up to US$10 MillionNASDAQ:ADAGAdagene Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:ADAG

Seu Histórico Recente

USOTC
PMAUF
Premier Investments (PK)
NYSE
FOB
Boyds Collection
NASDAQ
SCRM
Screaming Eagle Acquisit...
COIN
NAMGBP
ASX
SYL
Sylvastate
COIN
MTNGBP
MedToken
CSE
FNAU
Four Nines Gold
DGFX
KP3RBUSDT
Keep3r BSC Network
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados